We read with interest and some concerns the paper by Cénit et al. 1 in the current issue of Genes and Immunity, regarding the effect of signal transducer and activator of transcription 3 (STAT3) locus in autoimmune diseases. In brief, Cénit et al.
1 genotyped polymorphisms in the STAT3 region (rs3809758/rs744166/rs1026916/rs12948909) and analyzed inferred haplotypes in 860 inflammatory bowel disease and 1540 multiple sclerosis (MS) Spanish patients, and 1720 ethnically matched controls. The authors, controversially, found no evidence of association between STAT3 locus polymorphism and MS.
Cénit et al. addressed the discrepancy between their result and previously documented reports regarding the association of STAT3 polymorphisms and MS 2-5 through describing the probable role of epistasy in pathways involved in STAT3 signalling. We sincerely think that two points stated in the current report need to be more clarified:
(1) A recent meta-analysis of genome-wide association studies by De Jager et al. 3 that listed STAT3 as one of the genes with a suggestive role in at least two autoimmune disorders failed to replicate the initial association of STAT3. According to Jakkula et al., 5 a possible explanation for this failure to replicate the initial association was probably due to selecting the rs2293152, a most significantly associated regional single-nucleotide polymorphism (SNP), which resides just outside of the rs744166 containing the linkage disequilibrium region and has only limited linkage disequilibrium with the rs744166 (r 2 ¼ 0.35 in the HapMap2 CEU population), for the replication analysis. We think it would be advisable to exclude rs3809758 in candidate polymorphisms association studies of STAT3 and MS. (2) Although the authors acknowledged their reasons for adoption of the two regional single-nucleotide polymorphisms (rs744166/rs12948909), they did not provide satisfactory explanation for adoption of the other two regional single-nucleotide polymorphisms (rs3809758/rs1026916). Taken together, we strongly believe in order to exclude the association of STAT3 polymorphisms with MS in particular and any other autoimmune disorders in general, we should investigate polymorphisms in more than four regions within the gene.
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